Abstract. Angiopoietin-like 4 (ANGPTL4) promotes cancer cell migration through vessels and has been implicated in cancer metastasis. Our previous study identified a robust increase in ANGPTL4 mRNA expression in lung-metastasized tongue cancer (TC) cells. Therefore, the present study investigated the association of ANGPTL4 with lung metastasis and outcomes of patient with TC. ANGPTL4 expression in TC cells was investigated by immunohistochemical staining. Patients were classified into 'low (0‑30%)' and 'high (>30%)' ANGPTL4-expressing groups based on the proportion of ANGPTL4-positive TC cells. The high ANGPTL4-expression group included 15 of 48 patients with TC. Notably, a significantly greater proportion of patients with lung metastasis exhibited a high rate of ANGPTL4-expressing cancer cells compared with patients without lung metastasis (P=0.029). The overall 5-year survival rate was lower in the high (27%) ANGPTL4-expression group compared with the low (68%) ANGPTL4-expression group. Univariate and multivariate analyses revealed that patients with high ANGPTL4 expression in TC cells exhibited significantly lower overall survival (OS) rates [hazard ratio (HR), 2.99; 95% confidence interval (95% CI), 1.34‑6.69; P=0.008 and HR, 2.72; 95% CI, 1.14‑6.51; P=0.024, respectively]. High plasma ANGPTL4 concentrations as measured by ELISA were associated with lung metastasis (P<0.001). The optimal cut-point for prediction of TC lung metastasis was 9.1 ng/ml (P<0.001; 95% CI, 7.2‑10.9). The OS of patients with plasma ANGPTL4 above the cut-point was significantly lower than that of patients with plasma ANGPTL4 ≤9.1 ng/ml (P<0.001). These results suggest that a high level of ANGPTL4 in cancer cells and plasma may predict lung metastasis and/or a poor prognosis of patients with TC.

Introduction

The American Cancer Society estimated that 17,960 and 2,870 patients in the United States would be newly diagnosed with, and die as a result of tongue cancer (TC), respectively, in 2021 (1). While advances in surgical and radiation therapies have increased the average 5-year survival rate for patients with oropharyngeal cancer to 66%, this is still markedly lower than the >90% 5-year survival rate of patients with other cancer types, such as prostate and breast cancer (1). Most often, patient death is caused by regional and/or distant metastasis; thus, metastasis is indicative of a poor prognosis (2‑5). Squamous cell carcinoma (SCC) accounts for approximately 90% of oral and oropharyngeal malignancies in the United States (6), and commonly develops in the tongue (7). Notably, the average rate of nodal metastasis has been reported to be approximately 30% among patients with TC at initial evaluation, which is markedly higher than that of patients with other oral cavity
cancers (8,9). Moreover, several studies have identified a high rate of occult nodal metastasis (20–40%) in patients with TC who showed no evidence of regional spread during clinical or radiographic evaluation (8,10–15). Combined with the fact that the rate of TC has increased among young women over the last 20–30 years (16–18), these data highlight the urgent need for a novel approach to predict metastasis and start treatments at the early stage in patients with TC.

Angiopoietin-like 4 (ANGPTL4) belongs to a family of proteins that are structurally similar to the angiopoietins but do not bind to the angiopoietin receptors, tyrosine kinase with immunoglobulin-like and EGF-like domain 1 (TIE 1) and endothelial-specific receptor tyrosine kinase (TEK or TIE 2) (19). ANGPTL4 is a critical mediator of transmigration (20), and promotes trans-endothelial migration by up-regulating the expression of vascular endothelial adhesion molecule-1 (VCAM-1) in endothelial cells (21). Increased VCAM-1 expression, in turn, promotes the attachment of circulating cancer cells to the vessel walls, and facilitates extravasation and tumor establishment in other tissues. Clinically, ANGPTL4 expression is correlated with venous and lymphatic invasion in human SCC (22), and increased ANGPTL4 gene expression has been reported to promote lung metastasis in breast cancer (23).

Recently, we identified a robust increase in ANGPTL4 mRNA expression in lung-metastasized TC cells (24) that we induced to become highly metastatic to lymph nodes by repeating the passage in which the cells were injected into a nude mouse tongue and harvested from metastasized cervical lymph nodes (25). Together, these data suggest that ANGPTL4 is associated with TC lung metastasis.

To determine whether ANGPTL4 levels are predictive of TC lung metastasis, we investigated the clinical association of ANGPTL4 with TC lung metastasis and prognosis of the patients.

Materials and methods

Tissue samples, immunohistochemistry, and retrospective patient analysis. TC tissue samples were obtained via surgical resection from 48 Japanese patients (male 27, female 21, ranging 23–91 years old) with TC who complained of mostly uncurable tongue aphtha or ulcer and were admitted to the Kumamoto University Hospital between 2003 and 2015. Tissue samples were used with the approval of the internal ethics committee and all patients provided written informed consent. ICD-10 codes of TC comprise 2 C020, 28 C021, 7 C022 and 1 C028. In total, 23 of the patients with TC subsequently had lung metastasis later, and 13 also had lymph node metastasis. One patient developed lymph node, but not lung, metastasis. Heparinized plasma samples were obtained from 20 patients subsequently had lung metastasis later, and 13 also had lymph node metastasis.

Plasma ANGPTL4 assay. Blood samples were collected from 40 patients with TC who were admitted to the Kumamoto University Hospital between 2003 and 2017. Of these, 20 patients subsequently had lung metastasis later, and 13 also had lymph node metastasis. One patient developed lymph node, but not lung, metastasis. Heparinized plasma samples were obtained by centrifugation, and plasma ANGPTL4 levels were measured using a human ARP4 ELISA kit (ab99974, Abcam) according to the manufacturer’s instructions. Briefly, ANGPTL4 standards and plasma samples were pipetted into each well of a 96-well plate precoated with a human ANGPTL4-specific antibody. After ANGPTL4 capture, the plate was washed, and biotinylated anti-human ANGPTL4 antibody was added to each well. The plate was again washed to remove unbound biotinylated antibody before HRP-conjugated streptavidin was added to each well to initiate a color reaction that was proportional to the original amount of bound ANGPTL4. Stop Solution was used to change the resultant color from blue to yellow, and the intensity of the converted color was measured at 450 nm with a microplate reader (Model 550; Bio-Rad Laboratories).

Statistical analysis. Fisher's exact test was used to analyze potential associations between ANGPTL4 expression levels and all patients' clinicopathological parameters except age, which was instead analyzed via unpaired Student's t-test. Overall patient survival rates were evaluated using the Kaplan-Meier method and verified using the log-rank test. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for overall 5-year survival rate of patients in univariate and multivariate analyses. Plasma ANGPTL4 concentration values were analyzed using the unpaired Student's t-test. Values were expressed as the average ± standard deviation (SD) (n=20). An optimal cut-point of the plasma ANGPTL4 concentration for screening lung metastasis of TC was identified by bootstrapped ROC analysis under Liu's method using 1,000 bootstrap samples. The 95% confidence interval of the optimal cut-point was determined by normal distribution, under the ROC curve by binomial distribution, and sensitivity and specificity by binomial distribution. All statistical analyses were performed using the Stata Statistical Software: Release 17 for Windows (StataCorp LLC). A P-value <0.05 was considered to indicate statistically significance.

Results

ANGPTL4 expression in TC cells. To determine whether ANGPTL4 is involved in TC progression, tongue tissues were examined for ANGPTL4 expression in TC cells. Only a subset of TC cells expressed ANGPTL4. Of 48 patients analyzed,
33 (69%) and 15 (31%) were then classified into 'low' and 'high' ANGPTL4 expression groups, respectively (Fig. 1A–C), according to the percentage of ANGPTL4-expressing TC cells. ANGPTL4 was not expressed in noncancerous tongue epithelial cells (Fig. 1D).

Association of TC ANGPTL4 expression with lung metastasis and poor prognosis. To evaluate the impact of ANGPTL4 on TC lung metastasis, TC cells from patients with or without subsequent metastasis were examined for ANGPTL4 expression. No significant differences in patient age, sex, tumor histological grade, vascular invasion, or lymph node metastasis were observed between the high and low ANGPTL4 expression groups (Table I). In addition to patients at advanced pathological stage (P=0.031) and clinical stage (P=0.043), a significant greater proportion of patients with lung metastasis exhibited a high percentage of ANGPTL4 expressing cancer cells as compared to those without lung metastasis (P=0.029) (Table I). These findings suggested an association between high level of TC ANGPTL4 expression and lung metastasis.

Furthermore, the overall survival (OS) rate of patients with TC high rate of ANGPTL4 expression was significantly lower than that of patients with low ANGPTL4 expression (Fig. 2). The overall 5-year survival rate was more than twofold higher in patients in the low (68%) as compared to the high (27%) ANGPTL4 expression group (Table II). The median survival period of the patients in the two groups was 132 and 28 months, respectively. Univariate and multivariate analyses revealed that the OS rate of patients with high ANGPTL4-expressing TC was significantly lower than that of the patients with low ANGPTL4-expressing TC [hazard ratio (HR), 2.99; 95% confidence interval (CI), 1.34–6.69; P=0.08 and HR, 2.72; 95% CI, 1.14–6.51; P=0.024, respectively]. However, no significant difference in OS rate was identified in pathological and clinical stages in multivariate analysis. These results indicated that high expression of ANGPTL4 in TC cells is an independent predictor for poor prognosis and may suggest that ANGPTL4 promotes lung metastasis and poor patient outcomes in TC.

Table I. Association between cancer-cell ANGPTL4 expression and patient clinicopathological parameters in tongue cancer.

| Parameter                       | Low     | High    | P-value |
|---------------------------------|---------|---------|---------|
| Patients, n                     | 33      | 15      |         |
| Average age ± SD, years         | 61.0±15.4 | 61.8±14.3 | 0.860\(^{a}\) |
| Sex, n                          |         |         |         |
| Male                            | 16      | 11      | 0.129\(^{a}\) |
| Female                          | 17      | 4       |         |
| Histological grade\(^{b}\), n  |         |         |         |
| Well                            | 30      | 13      | 0.642\(^{b}\) |
| Moderate                        | 2       | 2       |         |
| Poor                            | 1       | 0       |         |
| Pathological stage\(^{c}\), n   |         |         |         |
| T1                               | 21      | 2       | 0.031\(^{b}\) |
| T2                               | 7       | 6       |         |
| T3                               | 4       | 5       |         |
| T4                               | 1       | 2       |         |
| Clinical stage\(^{d}\), n       |         |         |         |
| I                                | 21      | 2       | 0.043\(^{b}\) |
| II                               | 5       | 5       |         |
| III                              | 6       | 4       |         |
| IV                               | 1       | 4       |         |
| Vascular invasion, n            |         |         |         |
| (+)                              | 4       | 1       | 0.497\(^{b}\) |
| (-)                             | 29      | 14      |         |
| Lymph node metastasis, n        |         |         |         |
| (+)                             | 6       | 7       | 0.077\(^{b}\) |
| (-)                             | 27      | 8       |         |
| Lung metastasis, n              |         |         |         |
| (+)                             | 12      | 11      | 0.029\(^{b}\) |
| (-)                             | 21      | 4       |         |

\(^{a}\) P-values were calculated using an unpaired Student's t-test or \(^{b}\) Fisher's exact test. \(^{c}\) Well vs. moderate/poor; \(^{d}\) T1/T2 vs. T3/T4; \(^{e}\) I/II vs. III/IV. ANGPTL4, angiopietin-like 4.

Increase of plasma ANGPTL4 concentrations in TC patients with lung metastasis and poor prognosis. To further explore the relationship between ANGPTL4 and TC lung metastasis,
ANGPTL4 concentrations in plasma obtained on the first day of admission was measured. The plasma ANGPTL4 concentrations of the patients who subsequently developed lung metastasis later (12.6±3.1 ng/ml) were significantly higher than those of the patients without lung metastasis (6.2±2.8 ng/ml) \( (P<0.001) \) (Fig. 3). This result supports the likely association of high ANGPTL4 concentrations with lung metastasis in TC. ANGPTL4 levels in plasma/serum of controls (individuals without cancer or other disease) varied in reports. ANGPTL4 concentrations in the present study were comparable to those reported by Smart-Halajko et al (29); the median concentration was 7.7 (interquartile range, 5.9 to 11.0) ng/ml.

An optimal cut-point of plasma ANGPTL4 concentration for prediction of TC lung metastasis was determined to be 9.1 ng/ml \( (P<0.001; \text{95\% CI: 7.2-10.9}) \) with a sensitivity of 90.0% and specificity of 90.0% (Fig. 3; Figs. S1 and S2; Tables SI-SV). The OS rate of patients with plasma ANGPTL4 concentrations above the cut-point was significantly lower than that of patients with plasma ANGPTL4 less than or equal to the cut-point (Fig. 4). Twenty-eight of the TC patients were examined both cellular expression and plasma concentration of ANGPTL4. These were no significant difference in plasma ANGPTL4 concentrations of patients whose TC cells had high \( (10.51±4.70 \text{ ng/ml; } n=9) \) or low \( (9.36±4.75 \text{ ng/ml; } n=19) \) ANGPTL4 expression \( (P=0.55) \).

**Discussion**

ANGPTL4 has been reported to be involved in various processes required for cancer progression and metastasis. For example, ANGPTL4 mediates the induction of neovascularization (30) and increases cancer cell proliferation and tumor growth (31,32) through enabling cancer cells to evade apoptosis and acquire anoikis resistance (33). Moreover, ANGPTL4 has been reported to enhance vascular invasion (22,34,35). In fact, cancer cell ANGPTL4 expression has been reported to correlate with lymph node metastasis in esophageal (22,36), gastric (34), and oral squamous cell cancers (37). Consistent with these findings, we herein demonstrated for the first time that a high rate of ANGPTL4 expression in TC cells and high plasma ANGPTL4 concentration of TC patients are associated with lung metastasis (Table I and Fig. 3).

Only cancer cells in the collected TC tissues expressed ANGPTL4 (Fig. 1); accordingly, ANGPTL4 mRNA expression in TC tissues is derived from TC cells. The low survival rate of TC patients with high cellular ANGPTL4 protein expression (Fig. 2) agrees with a previous report of poor prognosis in patients with high ANGPTL4 mRNA expression in TC tissues (38). Given that ANGPTL4 has been shown to possess multiple cancer promoting effects, the high ANGPTL4 expression rates reported herein in TC, and the high ANGPTL4 mRNA expression levels previously identified in lung-metastasized breast cancer cells (23) and TC cells (24), strongly suggest that AMPTL4 promotes the metastasis of cancer cells, which is supported by finding that the OS rate of patients with high TC cell expression of...
ANGPTL4 was significantly lower than that of patients with low TC cell expression in multivariate analysis (Table II). Thus, high ANGPTL4 expression is likely an indicative marker for lung metastasis and poor prognosis in TC. Furthermore, OS rate of patients with plasma ANGPTL4 concentrations above the cut-point 9.1 ng/ml was significantly lower than that of patients with plasma ANGPTL4 concentrations at or below 9.1 ng/ml (Fig. 4). Using the tentative cut-point identified in the present study, TC patients with a plasma ANGPTL4 concentration above 9.1 ng/ml may be treated at an earlier stage, thereby enhancing survival with a lessened risk of lung metastasis.

Previous studies have shown that serum ANGPTL4 concentrations are approximately threefold higher in patients with esophageal cancer than in those with benign esophageal diseases. Furthermore, serum ANGPTL4 levels in esophageal cancer patients are ameliorated after surgical resection of the cancer tissues (36). Similarly, serum ANGPTL4 concentrations in patients with renal cell cancer have been reported to be twofold higher than in healthy controls and are associated with advanced clinical disease stages and metastasis (39). It is likely that in both cases, increased serum concentrations of ANGPTL4 enhanced cancer cell proliferation and tumor growth (31). Thus, ANGPTL4 concentrations may be indicative of disease progression in other types of cancers besides TC lung metastasis. This may also be supported by the fact that plasma ANGPTL4 levels were higher in cachectic cancer patients than in weight-stable cancer patients (40).

Hypoxia-inducible factor-1α (HIF-1α) induces ANGPTL4 expression in hepatocellular carcinoma (21) and HIF-1α expression is positively correlated with advanced clinical...
stages and metastasis in TC (41). Thus, it is presumed that HIF-1α-driven upregulation of TC cell ANGPTL4 secretion in combination with an increase of ANGPTL4-secreting TC cells synergistically elevated plasma ANGPTL4 concentrations in TC patients with lung metastasis (Fig. 3). ANGPTL4 promotes cancer cell growth (31,32) but there is a delay from an elevation of TC cell ANGPTL4 secretion to an increase in TC cells, and even a low level of ANGPTL4 secretion can lead to a significant increase in TC cells after a relatively long time. This may explain why there is no correlation of plasma ANGPTL4 concentrations with TC cell ANGPTL4 expression levels. Thus, assessing ANGPTL4 levels in both TC cells and in plasma may increases confidence in predicting lung metastasis and poor outcomes of patients with TC.

The present study demonstrated that lung metastasis and low OS rate in TC are associated with high rates of ANGPTL4 expression in TC cells (Table I and Fig. 2). This finding suggests that ANGPTL4 secretion promotes lung metastasis and mortality in TC patients, leading to increased plasma ANGPTL4 concentrations (Fig. 3), which induce an increase in ANGPTL4-driven cancer promoting effects (20-22,31-35). A schematic illustrating the possible promoting effects of ANGPTL4 on TC lung metastasis are presented in Fig. 5. ANGPTL4 secreted from TC cells promotes TC growth and anoikis resistance in the tongue facilitating TC cell migration to blood vessels and venous invasion into the circulation, followed by attachment to endothelial cells in the lung vessels, transendothelial migration and cancer nest growth in the lung. Future mechanistic studies to delineate the role of ANGPTL4 in TC in vitro using TC cells and in vivo using a mouse model would elucidate the association between ANGPTL4 and lung metastasis. Interestingly, a higher histological grade is a well-established predictor of low overall survival rates in TC (42); however, while the OS rate of the high ANGPTL4 expression group was much lower than that of the low ANGPTL4 expression group (Fig. 2), the histological grade exhibited by patients in the two groups were not different (Table I). Thus, high rates of ANGPTL4-expressing cancer cells and high plasma ANGPTL4 concentrations may be reliable predictive factors for lung metastasis and poor patient prognosis in TC. ANGPTL4-driven cancer promoting activities suggest a therapeutic effect of lowering AGPTL4; therefore, AGPTL4 is a potential therapeutic target for TC.

There are some limitations on the present study. Data from patients who had heterogeneous therapies were analyzed, which may affect prognostic evaluation for AGPTL4. Because the survey consisted of a homogenous ethnic group and in a relatively small patient number, the generalizability of the present results is potentially limited.

Acknowledgements

The authors would like to thank Dr Ameya Mahayan for English editing.

Funding

The present study was supported in part by a KAKENHI grant (17K11912) awarded by the Japan Society for the Promotion of Science.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TT and TI made substantial contributions to the conception, design and intellectual content of the present study. RI and TK performed immunohistochemistry. TI, MY and HO interpreted immunohistochemical staining results for patient classification. TT, MY, HO and HN collected tongue cancer tissue samples and patients' plasmas, and analyzed patients' clinicopathological data. TT, AI and SK contributed to the ELISA of ANGPTL4 in plasma. TT and KK performed statistical analysis of data. TT prepared the manuscript and TI and HN revised it critically for important intellectual content. MY, HO and HN confirmed the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent for tissue usage was obtained from the patients, and the use of these tissues was approved by The Internal Review Board of Kumamoto University Hospital (Rinri no. 1427; Kumamoto, Japan).

Patient consent for publication

Written informed consent for publication was obtained from the patients.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.
2. Kalnins IK, Leonard AG, Sako K, Razack MS and Shedd DP: Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am J Surg 134: 450-454, 1977.
3. Schuller DE, McGuirt WF, McCabe BF and Young D: The prognostic significance of metastatic cervical lymph nodes. Laryngoscope 90: 557-570, 1980.
4. Snow GB, Annyas AA, van Slooten EA, Bartelink H and Hart AA: Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci 7: 185-192, 1982.
5. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P and Molinari R: Prognostic significance of lymphatic spread in head and neck carcinomas: Therapeutic implications. Head Neck Surg 8: 67-73, 1985.
6. Chi AC, Day TA and Neville BW: Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin 65: 401-421, 2015.
7. Sano D and Myers JN: Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26: 645-662, 2007.
8. Ho CM, Lam KH, Wei WI, Lau SK and Lam LK: Occult lymph node metastasis in small oral tongue cancers. Head Neck 14: 395-399, 1992.
9. Myers EN and Simontal AA Jr: Cancer of the oral cavity. In: Cancer of the Head and Neck. 4th edition. Myers EN, Suen JY, Myers JN and Hanna EY (eds). Saunders, Philadelphia, PA, pp279-319, 2003.
10. Teichgraeber JF and Clairmont AA: The incidence of occult metastases for cancer of the oral tongue and floor of the mouth: Treatment rationale. Head Neck Surg 7: 15-21, 1984.

11. Cunningham MJ, Johnson JT, Myers EN, Schramm VL Jr and Thearle PB: Cervical lymph node metastasis after local excision of early squamous cell carcinoma of the oral cavity. Am J Surg 152: 361-366, 1986.

12. Fakih AR, Rao RS and Patel AR: Prophylactic neck dissection in squamous cell carcinoma of oral tongue: A prospective randomized study. Swed J Surg 5: 327-330, 1989.

13. Lydiatt DD, Robbins KT, Byers RM and Wolf PF: Treatment of stage I and II oral tongue cancer. Head Neck 15: 308-312, 1993.

14. Yuen AP, Wei WI, Wong YM and Tang KC: Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck 19: 583-588, 1997.

15. Yuen AP, Lam KY, Chan AC, Wei WI and Lam LK, Ho WK and Ho CM: Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. Am J Surg 177: 90-92, 1999.

16. Müller S, Pan Y, Li R and Chi AC: Changing trends in oral squamous cell carcinoma with particular reference to young patients: 1971-2006. The Emory University experience. Head Neck Pathol 2: 60-66, 2008.

17. Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, Muller S, Pan Y, Li R and Chi AC: Changing trends in oral squamous cell carcinoma with particular reference to young white women, age 18 to 44 years. J Clin Oncol 29: 1488-1494, 2011.

18. Toporcov TN, Znaor A, Zhang ZF, Yu GP, Winn DM, Wei Q, Vilensky M, Vaughan T, Thomson P, Talamini R, et al: Risk factors for head and neck cancer in young adults: A pooled analysis in the INHANCE consortium. Int J Epidemiol 44: 1069-1085, 2015.

19. Santulli G: Angiopoietin-like proteins: A comprehensive look. Int J Oncol 5: 4, 2014.

20. Huang RL, Teo Z, Chong HC, Zhu P, Tan MJ, Chong HC, Lam CR, Sng MK, Leong DT, Tan SM, et al: ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VC-cadherin and claudin-5 clusters. Blood 118: 3900-4002, 2011.

21. Li H, Ge C, Zhao F, Yan M, Hu C, Jia D, Tian H, Zhu M, Chen T, Jiang G, et al: Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology 54: 910-919, 2011.

22. Shibata K, Nakayama T, Hirakawa H, Hidaka S and Nagayasu T: Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol 63: 1054-1058, 2010.

23. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang, Y, Ishwaran H, et al: Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104: 6740-6745, 2007.

24. Tanaka T, Imanura T, Yoneda M, Irie A, Ogihara T, Yamauchi K, Nakagawa K, Shinohara M and Nakayama H: Enhancement of active MMP release and invasive activity of lymph node metastatic tongue cancer cells by elevated signal via the TNF-α-TNFRI1-TRADD-FADD-caspase-8 pathway and a possible involvement of angiopoietin-like 4 in lung metastasis. Int J Oncol 49: 1377-1384, 2016.

25. Tanaka T, Nakayama H, Yoshitake Y, Irie A, Nakagawa M, Kawamura K, Takamune Y, Yoshida R, Nakagawa Y, Ogihara T, et al: Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma. Cancer Sci 103: 455-463, 2012.

26. Koomagi R and Volm M: Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239-243, 1999.

27. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hachiya H, Ono T, Yamanoi A, Kohn H and Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: Possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7: 1325-1332, 2001.